Application of Monoclonal Antibody 44-3A6 in the cytological diagnosis of pleural effusion and histological correlation in lung carcinoma

Yew, Wing Wai; Kwan, Susan; Lam, Kwok Chi; Chiu, Kuo-Chin; Hsu, C.; Fu, K. H.; Radosevich, James A.

doi:10.1016/0169-5002(91)90027-4

Cited by 5 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have shown the utility of this MCA in the evaluation of both histological and cytological specie findings of these studies were again, in part confirmed, since there was (1) selective reactivity found within the neoplastic cases, (2) limited reactivity mens. [22][23][24][25][26][27][28][29][31][32][33] Th with benign or reactive tissues, and (3) good correlation of the cytological immunoreactivity with histological immunostaining. The conformation of these expected results, provides evidence that the new findings reported herein can be interpreted in a consistent manner with previously reported data.…”

Section: Discussionmentioning

confidence: 99%

Monoclonal antibody 44‐3A6 as an adjunct in cytodiagnosis of adenocarcinomas in body fluids

Cajulis

Szumel

Frias‐Hidvegi

et al. 1993

Diagnostic Cytopathology

View full text Add to dashboard Cite

Monoclonal antibody (MCA) 44-3A6 detects a cell-surface transmembrane phosphoprotein frequently expressed by pulmonary adenocarcinoma (AC) and associated with glandular differentiation. This antibody has been found to have utility in assessing routine formalin fixed paraffin-embedded pulmonary neoplasms, as well as the cytopathological evaluation of sputum and bronchial brushings. Recently, it has been shown to be useful in cytological diagnosis of pleural effusions. This study is directed at evaluating its effectiveness in detecting immunoreactive neoplastic cells in body fluids (BF) arising in other tissues. A retrospective cohort of 57 cases was studied, consisting of 36 pleural, 19 ascitic, and 2 pericardial BF. After evaluation of Papanicolaou-stained slides, the BF specimens were immunostained with MCA 44-3A6 using the avidin-biotin-peroxidase complex (ABC) method. In 29 cases, tissue sections of the primary tumors, were also available for immunostaining with MCA 44-3A6. Results showed that 39/42 (93%) of AC BF cases were positive and 28/42 (66%) stained intensely (3-4+) with 75-100% of the AC cells staining in each case. All of the 18 benign and non-AC malignant BF were negative. The staining patterns in the tissue sections of the 29 cases that had corresponding BF samples were similar. We conclude from this study that the MCA 44-3A6 (1) is useful in detecting cells consistent with AC in BF; (2) does not stain inflammatory cells or reactive mesothelial cells, thus helping distinguish reactive from malignant BF; and (3) frequency and pattern of expression in BF parallels its expression in tissue specimens. This study confirms that this MCA is a useful adjunct tool in the cytopathological evaluation of BF.

show abstract

Section: Discussionmentioning

confidence: 99%

Monoclonal antibody 44‐3A6 as an adjunct in cytodiagnosis of adenocarcinomas in body fluids

Cajulis

Szumel

Frias‐Hidvegi

et al. 1993

Diagnostic Cytopathology

View full text Add to dashboard Cite

show abstract

“…It is therefore an accessible therapeutic target for adenocarcinomas that represent approximately 40% of all cancers (cancercentre.com; cancer.org) [26] and includes the deadliest cancers of lung, colorectal, pancreatic, breast, prostate, and liver/intrahepatic bile duct, respectively (cdc.gov). Subsequent to the discovery of labyrinthin [27], which at the time was only referred to as the mouse monoclonal antibody MCA 44-3A6 antigen, numerous papers were published to elucidate the selective, yet broad association of the antigen with adenocarcinomas [28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43].…”

Section: J O U R N a L P R E -P R O O Fmentioning

confidence: 99%

Labyrinthin: A distinct pan-adenocarcinoma diagnostic and immunotherapeutic tumor specific antigen

Babich

Sharma

et al. 2022

Heliyon

View full text Add to dashboard Cite

“…It is therefore an accessible therapeutic target for adenocarcinomas that represent approximately 40% of all cancers (CTCA; Cancer.org) (Bray et al, 2018) and includes the deadliest cancers of lung, colorectal, pancreatic, breast, prostate, and liver/intrahepatic bile duct, respectively (CDC.gov). Subsequent to the discovery of labyrinthin (Radosevich et al, 1985), which at the time was only referred to as the mouse monoclonal antibody MCA 44-3A6 antigen, numerous papers were published to elucidate the selective, yet broad association of the antigen with adenocarcinomas (Babich et al, 2020; Banner et al, 1985; Cajulis et al, 1993; Combs et al, 1988a; Combs et al, 1988b; Duda et al, 1991; Lee et al, 1986; Lee et al, 1985; Piehl et al, 1988; Radosevich et al, 1991a; Radosevich et al, 1991b; Radosevich, 2000; Saleev et al, 2019; Siddiqui et al, 1992; Sinkule et al, 1991; Yew et al, 1991).…”

Section: Introductionmentioning

confidence: 99%

Topology and adenocarcinoma cell localization dataset on the labyrinthin biomarker

Babich¹,

Sharma²,

et al. 2021

Preprint

View full text Add to dashboard Cite

Structural analysis and detection of optimal cell surface localization of labyrinthin, a pan-adenocarcinoma target, was studied with respect to adenocarcinoma specificity vs. normal and non-adenocarcinoma cells. Patient-derived tissue microarray immunohistochemistry (IHC) was performed on 729 commercially prepared tissue blocks of lung, colon, breast, pancreas, prostate, and ovary cancers combined, plus a National Cancer Institute (NCI) tissue microarray derived from another 236 cases. The results confirmed that anti-labyrinthin mouse monoclonal MCA 44-3A6 antibody recognized adenocarcinomas, but not normal or non-adenocarcinoma cancer cells. The consensus of multiple topology analysis programs on labyrinthin (255 amino acids) estimate a type II cell membrane associated protein with an N-terminus signal peptide. However, because the labyrinthin sequence is enveloped within the 758 amino acids of the intracellular aspartyl/asparaginyl beta-hydroxylase (ASPH), a purported tumor associated antigen, standard IHC methods that permeabilize cells can expose common epitopes. To circumvent antibody cross-reactivity, cell surface labyrinthin was distinguished from intracellular ASPH by FACS analysis of permeabilized vs non-permeabilized cells. All permeabilized normal, adeno-and non-adenocarcinoma cells produced a strong MCA 44-3A6 binding signal, likely reflecting co-recognition of intracellular ASPH proteins along with internalized labyrinthin, but in non-permeabilized cells only adenocarcinoma cells were positive for labyrinthin. Confocal microscopy confirmed the FACS results. Labyrinthin as a functional cell-surface marker was suggested when: 1) WI-38 normal lung fibroblasts transfected with labyrinthin sense cDNA displayed a cancerous phenotype; 2) antisense transfection of A549 human lung adenocarcinoma cells appeared more normal; and 3) MCA44-3A6 suppressed A549 cell proliferation. Collectively, the data indicate that labyrinthin is a unique, promising adenocarcinoma tumor-specific antigen and therapeutic target. The study also raises a controversial issue on the extent, specificity, and usefulness of ASPH as an adenocarcinoma tumor-associated antigen.

show abstract

Application of Monoclonal Antibody 44-3A6 in the cytological diagnosis of pleural effusion and histological correlation in lung carcinoma

Cited by 5 publications

References 14 publications

Monoclonal antibody 44‐3A6 as an adjunct in cytodiagnosis of adenocarcinomas in body fluids

Monoclonal antibody 44‐3A6 as an adjunct in cytodiagnosis of adenocarcinomas in body fluids

Labyrinthin: A distinct pan-adenocarcinoma diagnostic and immunotherapeutic tumor specific antigen

Topology and adenocarcinoma cell localization dataset on the labyrinthin biomarker

Contact Info

Product

Resources

About